Navigation Links
Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009
Date:8/24/2009

SOUTH SAN FRANCISCO, Calif., Aug. 24 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

Oral presentation details are as follows:

Title: First in Patient Experience with a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128): Evaluation in Patients with High Platelet Reactivity During Clopidogrel Therapy (Program #2678)

Presenter: Paul A. Gurbel, M.D., Director, Sinai Center for Thrombosis Research, Baltimore, Md.

Date: Monday, August 31, 4:45-5:00 p.m.

Location: Sofia Room, Zone 1

Title: The Clopidogrel-Insensitive Pool of P2Y12 Receptors Exposed Upon Platelet Activation Contributes to Thrombus Formation and Can Be Blocked by Elinogrel, a Direct Acting, Reversible P2Y12 Inhibitor (Program #5115)

Presenter: Helena Haberstock-Debic of Portola

Date: Wednesday, September 2, 11:15-11:30 a.m.

Location: Stockholm Room, Zone 4

About Elinogrel

Elinogrel is the only direct acting, reversible, i.v. and oral P2Y12 ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Because of its properties, elinogrel has the potential to provide significant clinical advantages compared to Plavix(R)* (clopidogrel), the current standard of care; newer agents, such as prasugrel; and those in development, by lowering the risk of ischemic events due to clot formation and reducing the risk of bleeding. In addition, elinogrel is the only compound in development that can be administered intravenously in the hospital and orally in the chronic setting.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y12 ADP receptor antagonist and potential competitor for Plavix* (clopidogrel), is licensed to Novartis. Both betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.

Portola also has proprietary pipeline programs focused on the discovery and development of novel, specific Syk and JAK inhibitors to treat cancer and inflammatory diseases; a thromboxane receptor antagonist, which is an aspirin replacement product for patients intolerant to aspirin; and a novel anticoagulant antidote program with the potential to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit www.portola.com.

*Plavix(R) is a registered trademark of Sanofi/Aventis and Bristol Myers Squibb.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a ... Seymour , MD, MPH, will present information about the company,s programs ... in New York City . ... Windsor Room at 5:30PM EST. Registered attendees can request a one ... City . --> New York City ...
(Date:2/6/2016)... ... 2016 , ... The Center for Excellence in Education (CEE) will sponsor a ... Wednesday February 10, 2016. This Bite of Science session, hosted by the Smithsonian-Mason ... 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. The ...
(Date:2/5/2016)... 5, 2016 On Thursday, February 11, ... for community, health and disaster services, and the ... to enhance care coordination and service delivery for the ... need and to better connect service providers to the ... San Diego has handled more than ...
(Date:2/4/2016)... LEXINGTON, Massachusetts , February 4, 2016 - New ... --> - New FDA action date of July ... date of July 22, 2016   - ... the U.S. in the past decade indicated for the treatment of signs and ... Lifitegrast has the potential to be the only product approved in the ...
Breaking Biology Technology:
(Date:1/13/2016)... York , January 13, 2016 ... Research has published a new market report titled - Biometric ... Trends, and Forecast, 2015 - 2023. According to the report, ... 2014 and is anticipated to reach US$1,625.8 mn by ... to 2023. In terms of volume, the biometric sensors ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... United Kingdom , Jan. 8, 2016   Bruin ... products, today announced the closing of a $9 million financing. ... from the financing will be used to accelerate the commercialization ... detecting early-stage pressure ulcers. United Kingdom ... CE Mark approval. The device,s introduction has been met with ...
Breaking Biology News(10 mins):